Regeneron Pharmaceuticals 8-K
PositiveEarningsGuidance
Dupixent drove Sanofi collaboration growth; Development Balance repayment is expected to lift collaboration revenue from Q3.
Filed 2026-07-30 06:48 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q2 2026 results with updated FY2026 guidance. Revenue grew 17% Y/Y, while GAAP net income fell 7% and non-GAAP diluted EPS rose 11%. The Sanofi Development Balance was fully repaid; Regeneron expects this to lift Sanofi collaboration revenue beginning in Q3. FDA and EMA accepted cemdisiran applications for review for generalized myasthenia gravis.
Key Figures
| Metric | Q2 2026 | Q2 2025 | Y/Y |
|---|---|---|---|
| Revenue | $4.29B | $3.68B | 17% |
| Operating income | $1.29B | $1.08B | 20% |
| GAAP net income | $1.30B | $1.39B | (7%) |
| Non-GAAP net income | $1.54B | $1.42B | 8% |
| GAAP diluted EPS | $12.23 | $12.81 | (5%) |
| Non-GAAP diluted EPS | $14.29 | $12.89 | 11% |
- Product sales were led by Dupixent, with global sales recorded by Sanofi of $6.0B (+38%); EYLEA HD U.S. sales were $596M (+52%), while global Libtayo sales were $489M (+30%). EYLEA U.S. sales fell 45%, reflecting lower demand amid competition and patient transition to EYLEA HD.
- Sanofi collaboration revenue rose 51% to $2.17B; Regeneron’s share of antibody commercialization profits increased to $2.03B from $1.28B, primarily on higher Dupixent sales. The Sanofi Development Balance repayment ends its reduction of collaboration revenue from Q3.
- First-half operating cash flow was $1.89B vs $2.19B; free cash flow was $1.42B vs $1.74B. Regeneron repurchased $1.2B of stock in Q2 and $2.0B in H1; cash and marketable securities were $17.8B and long-term debt was $1.99B at 6/30/2026. The Q2 gross margin on net product sales was 78% GAAP and 87% non-GAAP; bulk manufacturing in Limerick returned to normal by quarter-end.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| R&D (GAAP) | FY2026 | $6.5B-$6.635B | $6.45B-$6.68B | Narrowed |
| R&D (non-GAAP) | FY2026 | $5.95B-$6.05B | $5.9B-$6.1B | Narrowed |
| Selling, general and administrative expense (GAAP) | FY2026 | $2.83B-$2.96B | $2.86B-$3.04B | Lowered |
| Selling, general and administrative expense (non-GAAP) | FY2026 | $2.5B-$2.6B | $2.5B-$2.65B | Narrowed |
| Gross margin on net product sales (GAAP) | FY2026 | 78%-79% | 77%-78% | Raised |
| Gross margin on net product sales (non-GAAP) | FY2026 | 84%-85% | 83%-84% | Raised |
| Cost of collaboration and contract manufacturing (GAAP) | FY2026 | $985M-$1.035B | $955M-$1.035B | Narrowed |
| Cost of collaboration and contract manufacturing (non-GAAP) | FY2026 | $970M-$1.02B | $940M-$1.02B | Narrowed |
| Capital expenditures | FY2026 | $1.03B-$1.1B | $1.1B-$1.2B | Lowered |
| Effective tax rate (GAAP) | FY2026 | 13%-14% | 12%-14% | Narrowed |
| Effective tax rate (non-GAAP) | FY2026 | 14%-15% | 13%-15% | Narrowed |
Guidance excludes business-development transactions not completed as of 7/30/2026.
Investor Takeaways
- Q3 Sanofi collaboration revenue will show the effect of the repaid Development Balance; Regeneron cited a meaningful step-up in collaboration profits.
- Watch for the FDA’s cemdisiran decision, targeted for 11/2026, and the European Commission decision anticipated in H2 2027.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3